TrialThe Lancet. Neurology2023

Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study.

Volkan Granit et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.